EGFR and neoplasm: As the results from these preclinical models demonstrated anti‐tumor activity of DS‐1205c in combination with a TKI in EGFR‐mutant NSCLC (T790M‐negative) tumors, we conducted a first‐in‐human Phase 1 study of DS‐1205c in combination with gefitinib in subjects with metastatic or unresectable EGFR‐mutant NSCLC.